Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03398200 | Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma | completed | Phase 2 | 99 | Omar AljitawiOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02874742 | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 224 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 4, 2025 |
| clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03187223 | Bendamustine and Melphalan in Myeloma(BEB-2) | completed | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01718743 | Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04436029 | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | completed | Phase 2 | 5 | Cartesian TherapeuticsINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03233776 | Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT(AFFECT-1) | completed | Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04099901 | Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial(AFFECT-2) | completed | Phase 2 | 88 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT00482261 | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | completed | Phase 2 | 150 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | completed | Phase 2 | 61 | TakedaINDUSTRY | 6 | Jul 3, 2024 | clinicaltrials |
| NCT04379817 | Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients(SCARLET) | completed | Phase 2 | 23 | Jules Bordet InstituteOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT01283997 | Prevention of Treatment Induced Neuropathy in Multiple Myeloma | completed | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma(EVOLVE) | completed | Phase 1 / Phase 2 | 165 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | completed | Phase 2 | 62 | Amsterdam UMC, location VUmcOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT02728102 | Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | completed | Phase 2 | 203 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 7, 2024 | clinicaltrials |
| NCT01063907 | A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 95 | Kyowa Kirin Co., Ltd.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT04028115 | Bone Healing During Ninlaro Exposure(BONE) | completed | Phase 2 | 30 | Thomas LundOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02891811 | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | completed | Phase 2 | 124 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 29, 2024 | clinicaltrials |
| NCT03450057 | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment(DARE) | completed | Phase 2 | 38 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT02119468 | Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00019097 | Vaccine Therapy in Treating Patients With Multiple Myeloma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | completed | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04682405 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT01913730 | Maintenance Therapy With Subcutaneous Bortezomib | completed | Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)(GMMG-BIRMA) | completed | Phase 2 | 12 | University of Heidelberg Medical CenterOTHER | 1 | Nov 24, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 7, 2025source: clinicaltrials